SEC Form 4 research
| Issuer | HEMISPHERX BIOPHARMA INC |
|---|---|
| Tickers | HEB, AIM |
| Reporting owners | 22 |
| Officers and directors | 11 |
| Last public filing | 2026-11-06 |
| Available | Trade date | Reporting owners | Code | Shares | Price | Reported value |
|---|---|---|---|---|---|---|
| 2026-11-06 | 2026-11-06 | Equels Thomas K | P | 20,299 | $0.16 | Not reported |
| 2026-10-26 | 2026-10-23 | Equels Thomas K | P | 31,675 | $0.16 | Not reported |
| 2026-10-23 | 2026-10-22 | Equels Thomas K | P | 31,250 | $0.16 | Not reported |
| 2026-09-18 | 2026-09-17 | Equels Thomas K | P | 24,000 | $0.21 | Not reported |
| 2026-09-17 | 2026-09-16 | Equels Thomas K | P | 11,000 | $0.21 | Not reported |
| 2026-09-16 | 2026-09-15 | Equels Thomas K | P | 22,000 | $0.22 | Not reported |
| 2026-09-15 | 2026-09-14 | Equels Thomas K | P | 5,900 | $0.22 | Not reported |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.